Yanxia Chen1, Xiangjian Zhang2, Junna He3, Yanzhao Xie3, Yang Yang3. 1. Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 2. Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; Hebei Key Laboratory of Vascular Homeostasis and Hebei Collaborative Innovation Center for Cardio-cerebrovascular Disease, Shijiazhuang, Hebei, China. Electronic address: zhang6xj@aliyun.com. 3. Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Abstract
BACKGROUND: Glucagon-like peptide 1 (GLP-1) analogs administered before or after cerebral ischemia have been shown to provide neuroprotection. Here, we explored whether delayed administration of a GLP-1 analog, liraglutide, could improve long-term functional recovery and promote angiogenesis after stroke. MATERIALS AND METHODS: In the present study, mice were established as a focal cerebral cortical ischemia model and were intraperitoneally administered liraglutide or normal saline (NS) daily for 14 consecutive days, starting 1 day after cerebral ischemia. The neurological deficits were evaluated using rotarod test. The microvessel density (MVD) and endothelial cell (EC) proliferation were assessed by immunohistochemical staining. The expression of vascular endothelial growth factor (VEGF) was assessed by Western blot analysis. RESULTS: Liraglutide significantly reduced infarct volume and improved the rotarod test scores, compared with mice treated with NS. Liraglutide also greatly increased the MVD and EC proliferation and simultaneously upregulated the expression of VEGF in the cerebral ischemic area. CONCLUSIONS: These results demonstrated that liraglutide promoted angiogenesis and long-term recovery of cerebral ischemia through increasing the expression of VEGF.
BACKGROUND:Glucagon-like peptide 1 (GLP-1) analogs administered before or after cerebral ischemia have been shown to provide neuroprotection. Here, we explored whether delayed administration of a GLP-1 analog, liraglutide, could improve long-term functional recovery and promote angiogenesis after stroke. MATERIALS AND METHODS: In the present study, mice were established as a focal cerebral cortical ischemia model and were intraperitoneally administered liraglutide or normal saline (NS) daily for 14 consecutive days, starting 1 day after cerebral ischemia. The neurological deficits were evaluated using rotarod test. The microvessel density (MVD) and endothelial cell (EC) proliferation were assessed by immunohistochemical staining. The expression of vascular endothelial growth factor (VEGF) was assessed by Western blot analysis. RESULTS: Liraglutide significantly reduced infarct volume and improved the rotarod test scores, compared with mice treated with NS. Liraglutide also greatly increased the MVD and EC proliferation and simultaneously upregulated the expression of VEGF in the cerebral ischemic area. CONCLUSIONS: These results demonstrated that liraglutide promoted angiogenesis and long-term recovery of cerebral ischemia through increasing the expression of VEGF.
Authors: Mark P Maskery; Christian Holscher; Stephanie P Jones; Christopher I Price; W David Strain; Caroline L Watkins; David J Werring; Hedley Ca Emsley Journal: J Cereb Blood Flow Metab Date: 2020-09-20 Impact factor: 6.200
Authors: Maria Jose Carranza-Naval; Angel Del Marco; Carmen Hierro-Bujalance; Pilar Alves-Martinez; Carmen Infante-Garcia; Maria Vargas-Soria; Marta Herrera; Belen Barba-Cordoba; Isabel Atienza-Navarro; Simon Lubian-Lopez; Monica Garcia-Alloza Journal: Front Aging Neurosci Date: 2021-12-16 Impact factor: 5.750
Authors: Julie R Lundgren; Kristine Færch; Daniel R Witte; Anna E Jonsson; Oluf Pedersen; Torben Hansen; Torsten Lauritzen; Jens J Holst; Dorte Vistisen; Marit E Jørgensen; Signe S Torekov; Nanna B Johansen Journal: Cardiovasc Diabetol Date: 2019-10-05 Impact factor: 9.951